We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novonesis AS | TG:NZM2 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.28 | -0.49% | 56.94 | 56.50 | 56.84 | 57.98 | 56.68 | 57.98 | 786 | 16:09:27 |
From Jun 2024 to Jul 2024
June 21, 2024
Company announcement No. 22
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novonesis, that as of yesterday, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 A-shares (nominally DKK 107,487,200) and 65,672,555 B-shares (nominally DKK 131,345,110) corresponding to 25.50% of the entire issued share capital and 63.35% of the total voting rights in Novozymes A/S, part of Novonesis Group.
| Contact information | ||
| Tobias Bjorklund+45 3077 8682tobb@novonesis.com | ||
| Anders Enevoldsen+45 5350 1453adev@novonesis.com | ||
| Disa Tuominen+45 6038 5826ditu@novonesis.com | ||
Attachment
1 Year Novonesis AS Chart |
1 Month Novonesis AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
